Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C: Open Issues and Future Perspectives
Currently, two direct-acting antivirals (DAAs) show well-established efficacy against hepatitis C virus (HCV), namely, first-wave protease inhibitors telaprevir and boceprevir. Most clinical trials have examined DAAs in combination with standard of care (SOC) regimens. Future therapeutic drugs were...
Saved in:
Main Authors: | Hee Bok Chae, Seon Mee Park, Sei Jin Youn |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2013-01-01
|
Series: | The Scientific World Journal |
Online Access: | http://dx.doi.org/10.1155/2013/704912 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Glucose Metabolism Changes in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals
by: Sylvia Drazilova, et al.
Published: (2018-01-01) -
Successful Antiviral Treatment with Direct-Acting Antivirals for Hepatitis C Virus Infection during Peritransplant Period in a Kidney Transplant Recipient
by: Giovanni Varotti, et al.
Published: (2021-01-01) -
Economic evaluation of pan-genotypic generic direct-acting antiviral regimens for treatment of chronic hepatitis C in Iran: a cost-effectiveness study
by: Seyed Moayed Alavian, et al.
Published: (2022-06-01) -
Direct-Acting Antivirals in Hepatitis C Treatment for Renal Impairment: Liver Safety Concerns and Effectiveness in Peritoneal Dialysis
by: Hsuan-Yu Hung, et al.
Published: (2024-12-01) -
Immunological Dynamics Associated with Direct-Acting Antiviral Therapies in Naive and Experimented HCV Chronic-Infected Patients
by: Grenda Leite Pereira, et al.
Published: (2019-01-01)